Smoking Cessation Intervention in Respiratory Inpatients
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Prospective, open-label, parallel-group, 52-week trial comparing varenicline in combination
with behavioral support with one session of behavioral support alone.
Eligible patients were smokers hospitalized due to a) acute exacerbation of chronic
obstructive pulmonary disease (COPD), or b) bronchial asthma attack, or c) community-acquired
pneumonia (CAP).
The primary outcome was the success rate (%) at week 52. Secondary outcomes were quality of
life (QoL) alterations on the domains of the 36-Item Short Form Health Survey (SF36) and
investigation of possible predictors for smoking abstinence.